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Abstract
Background: A shift from Th1 to Th2 as well as an increase in Treg CD4+T cell subsets has been reported in septic patients
(SP). Furthermore, these patients display modulation of monocyte function, with reduced production of pro-inflammatory
cytokines upon LPS stimulus, which resembles the phenotype of alternatively activated macrophages. In this study, we
evaluated the percentages of T cells differentiated into Th1, Th17 and Treg subsets, as well as the percentage of monocytes
expressing markers of alternatively activated monocytes/macrophages (AAM) in SP.
Methodology/Principal Findings: Peripheral blood mononuclear cells (PBMC) were obtained from 32 healthy volunteers
(HV) and from SP at admission (D0, n=67) and after 7 days of therapy (D7, n=33). Th1 and Th17 (CD3+CD82) lymphocytes
were identified by the intracellular detection of IFN-c and IL-17, respectively, spontaneously and after PMA/Io stimulation,
and Treg cells were identified by Foxp3+CD127- expression. Monocytes were evaluated for CD206 and CD163 expression.
Absolute numbers of CD4+T lymphocytes were measured in whole blood samples by flow cytometry. The Mann-Whitney or
Wilcoxon test was applied, as appropriate. The percentage of Th1 cells was lower in SP than in HV at admission after PMA/Io
stimulation, whereas the percentage of Th17 cells was higher. In patients’ follow-up samples, a higher percentage of Th1
cells and a lower percentage of Th17 cells were observed on D7 compared with the D0 samples. Treg cells remained
unchanged. Septic patients showed a markedly increased proportion of monocytes expressing CD163 and CD206.
Conclusions/Significance: Upon in vitro stimulus, the percentage of T helper lymphocytes producing IL-17 was higher in SP
than in HV at admission, and the percentage producing IFN-c was lower, a pattern that was reversed during follow-up. The
increased expression of CD163 and CD206 indicates that monocytes may acquire the AAM phenotype during sepsis.
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Introduction
Inflammatory responses are modulated during sepsis, and
different components of inflammation are upregulated or down-
regulated, depending on the type of cell and its function [1]. It has
been suggested that a state of hyporesponse or immune paralysis
follows the initial inflammatory response in humans and exper-
imental sepsis, which is related to susceptibility to nosocomial
infections and late lethality [2–5].
A reduction in lymphocyte populations and increased apoptosis
have been observed during sepsis, with a shift from a T helper
(Th)1 to a Th2 pattern of cytokine expression [2]. Two other
CD4+ T lymphocyte subpopulations, regulatory T cells (Treg) and
Th17 cells, have been characterized and found to have major
antagonistic effects on the inflammatory response, which may play
a role in sepsis [6].
Tregs suppress the activity of lymphocytes and macrophages
[7]. Increased proportions of Tregs have been described in human
and experimental sepsis [8–10], yet their role in sepsis-induced
immune suppression has not been elucidated [11–13]. Th17 cells
have recently been characterized as a distinct CD4+ T subset [14].
Naı ¨ve CD4+ T cells will differentiate into Th17 cells in the
presence of IL-6 and transforming growth factor (TGF) -b
[6,15,16]. Different pathogens may trigger the induction of IL-
17, and protective and detrimental roles for IL-17 have been
shown in experimental infections; however, information on IL-17
in clinical sepsis is scarce.
The distinct CD4+ T cell subsets, among other cell types, play
major roles during the differentiation of macrophages into distinct
phenotypes. IFN-c induces classical macrophage activation,
leading to enhanced microbicidal or tumoricidal activity and the
production of high levels of pro-inflammatory cytokines as well as
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alternative activation, resulting in increased arginase activity
(repair activity) and enhanced mannose receptor expression. IL-
10, among other stimuli, induces a more profound monocyte
deactivation, which leads to the production of high levels of IL-10
and low levels of IL-12 [17,18]. IL-4/IL-13- and IL-10-induced
macrophages are referred to as alternatively activated macro-
phages (AAM), or more precisely as wound-healing and regulatory
macrophages, respectively [18]. Interestingly, IL-4 and or IL-13
induce AAM that express CD206 [19], while IL-10 induces AAM
that express CD163 on the cell surface [20]. IL-21, one of the
cytokines related to Th17 cells, is implicated in Th2 effector
function and alternative macrophage differentiation [21]. Recent
evidence indicates that Tregs induce an AAM phenotype, along
with the expression of both receptors, increased phagocytosis and
suppressed production of pro-inflammatory cytokines upon LPS
stimulation [22].
Monocyte functions have been shown to be modulated during
sepsis [23–28]. Decreased expression of CD14 and HLA-DR on
the surface of monocytes [23–25] and low production of
inflammatory cytokines by peripheral blood cells have been found
in septic patients [3,4,26]. Interestingly, monocytes that were
hyporesponsive with respect to the production of inflammatory
cytokines [24] showed preserved reactive oxygen species genera-
tion [27]. It is conceivable that these functional changes may
indicate the differentiation of monocytes into the phenotypes of
alternatively activated cells.
Given that the interplay between T lymphocyte subpopulations
and monocytes/macrophages may have a role in the pathophys-
iology of sepsis, we evaluated T helper differentiation into Th1,
Th17 and Treg cells and the percentage of monocytes expressing
CD206 and CD163, which are markers of AAM, in septic
patients.
Materials and Methods
Patients and Healthy Volunteers
This study was approved by the ethics committees of the
participating hospitals, Sao Paulo Hospital (Study number 1477/
06), Albert Einstein Hospital (Study number 07/549) and Sirio
Libanes Hospital (Study number 2006/27). All participants were
enrolled after informed consent was obtained. Patients admitted to
the Intensive Care Units from the 3 hospitals, localized in Sao
Paulo, Brazil, were enrolled with clinical diagnoses of sepsis
according to the ACCP/SCCM consensus conference [29].
Samples were obtained from 67 septic patients at admission
(D0). Thirty-three of the patients had a second sample collected
after 7 days (D7) of therapy. Clinical and epidemiological data
were obtained from patients during their stay in the Intensive Care
Units. The outcomes are reported as in-hospital mortality. An
attempt to match age and gender was made using 32 healthy
volunteers with similar characteristics to the septic patients.
Peripheral Blood Mononuclear Cell (PBMC) Isolation,
Cryopreservation and Thawing
Fifty milliliters of blood was collected in sodium heparin-treated
tubes (BD Biosciences, Franklin Lakes, NJ, USA). Peripheral blood
mononuclear cells were obtained using the Ficoll gradient method
(Ficoll-Paque PLUS; GE Healthcare Bio-Sciences AB, Uppsala,
Sweden), frozen in fetal bovine serum (Invitrogen-Gibco, Gai-
thersburg, MD, USA) with 10% dimethyl sulfoxide (Calbiochem,
La Jolla, CA, USA) and stored in liquid nitrogen until use. Upon
thawing, the cells were washed and suspended in R10 (RPMI 1640
medium supplemented with 10% fetal bovine serum, 1% HEPES
buffer solution 100 mM, 1% L-glutamine 200 mM, 1% sodium
pyruvate 100 mM, 1% penicillin/streptomycin 1006, and 0.1%
2-mercaptoethanol 55 mM, all from Invitrogen). The standard cell
concentration was 1610
6 cells/mL.
Intracellular Staining for IL-17A and IFN-c
PBMCs were stimulated with 20 ng/mL phorbol 12-myristate
13-acetate (PMA) and 0.5 mL 1 mM ionomycin (Io) (Sigma, Saint
Louis, MO, USA) at 37uC and under 5% CO2 for 30 minutes.
Brefeldin A (1 mg/mL; Sigma) was added, and the samples were
incubated for an additional 15 h. PMA/ionomycin triggers a
strong production of cytokines in vitro and is largely used to
evaluate intracellular detection of cytokines from different T
lymphocyte subpopulations [30].
The cells were stained with CD3-allophycocyanin-cyanine 7
conjugate (APC-Cy7) and CD8-perididin chlorophyll protein
(PerCP) (clones SK7 and SK1, respectively, both from BD
Biosciences) to identify the T helper lymphocyte population
(CD3+CD8-) [30]. After washing with FACS buffer (0.15 M PBS
(8.0 g NaCl, 0.2 g KH2PO4, 1.15 g Na2HPO4, 0.2 g KCl,
distilled water to obtain 1 L, pH 7.2), 0.1% BSA (Sigma) and
2.0 mM EDTA (Sigma)), the samples were fixed and permea-
bilized by adding 750 mL2 6lysis solution (BD Biosciences) with
0.05% Tween 20 (Casa Americana de Artigos para Laboratorio,
Sao Paulo, SP, Brazil) in the dark for 10 minutes. After
centrifugation, the supernatant was discarded, and the cells were
intracellularly stained to detect IL-17 and IFN-c, using IL-17A-
phycoerythrin (PE, clone eBio64CAP17, eBiosciences, San Diego,
CA, USA) and IFN-c phycoerythrin-cyanine 7-conjugated (PE-
Cy7, clone B27, BD Biosciences) for 30 minutes in the dark. The
samples were washed with FACS buffer and resuspended in
fixation buffer (PBS supplemented with 1% paraformaldehyde;
Polysciences, Warrington, PA, USA). T cells were identified
based on CD3-APC-Cy7 staining and forward scatter versus side
scatter parameters. In total, 70,000 events were acquired. CD4 T
cells were gated as CD3+CD82, and the percentages of cells
producing IFN-c or IL-17 were determined using thresholds
based on unstimulated samples. Cells producing IFN-c or IL-17
were considered for Th1 or Th17 cell characterization (Figure 1).
T Regulatory Cell Immunophenotyping
PBMCs were surface stained with CD45-APC-Cy7 (clone 2D1),
CD3-PE-Cy7 (clone SK7), CD4-PerCP (clone SK3) and CD127
Alexa Fluor 647 (clone hIL-7R-M21) (all antibodies from BD
Biosciences, San Jose, CA, USA) for 15 minutes at room
temperature in the dark. The isotype mIgG1-Alexa Fluor 647
(clone MOPC-21 from BD Biosciences) was used as a control.
After washing with FACS buffer, the cells were fixed, permeabi-
lized and intracellularly stained with anti-forkhead box P3
(Foxp3)-PE antibody (clone 236A/E7) or isotype mIgG1-PE for
30 minutes at 4uC with buffers from an eBiosciences kit (San
Diego, CA, USA). The samples were washed twice and
resuspended in FACS buffer. Fifty thousand events were acquired
from a gate based on CD3+ staining and forward scatter versus
side scatter parameters. In analyses T helper lymphocytes were
gated as CD45+CD3+CD4+ and Tregs characterized as CD127-
Foxp3+ cells, as previously suggested [31,32]. The analysis strategy
is shown in Figure 2.
Cell Surface CD163 and CD206 on Monocytes
PBMCs were surface stained with CD14-PerCP (clone MwP9),
CD16-APC-Cy7 (clone 3G8), CD163-PE (clone GHI/61) and
CD206-fluorescein isothiocyanate (FITC, clone 19.2) (all anti-
bodies from BD Biosciences) for 15 minutes at room temperature
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clone MOPC-21 from BD Biosciences) were used as controls for
CD163 and CD206. After washing with FACS buffer, the cells
were resuspended in fixation buffer. Twenty thousand events
were acquired using a gate based on CD14-positive staining and
forward scatter versus side scatter parameters, and the percent-
ages of cells expressing CD163 or CD206 were determined using
thresholds based on the isotype controls (Figure 3). Additional
analysis of CD163 and CD206 expression was performed in
monocytes subsets combining the expression of CD14/CD16 as
follows: CD14++CD162, CD14++CD16+ and CD14+CD16+
cells.
Absolute CD4+T Lymphocyte Counting
Blood samples were collected in EDTA vacutainer tubes (BD
Biosciences, Franklin Lakes, NJ, USA). Absolute numbers of
CD4+T lymphocytes were counted using Multitest antibodies
and TruCount tubes (BD Biosciences, San Jose, California, USA)
Figure 1. Strategy for the analysis of Th1 and Th17 lymphocytes. Dot plots shown are representative of one healthy volunteer and one
septic patient. T cells were identified based on CD3-APC-Cy7 staining and forward scatter versus side scatter parameters. For the analyses, T helper
cells were gated as CD3+CD82, and the percentages of cells producing IFN-c or IL-17 were determined with the quadrants established based on the
control samples.
doi:10.1371/journal.pone.0037393.g001
Figure 2. Strategy for the analysis of T regulatory lymphocytes. Dot plots shown are representative of one healthy volunteer and one septic
patient. Fifty thousand events were acquired with CD3+ gating and forward scatter versus side scatter parameters. For the analyses, the first gate was
determined based on low SSC and high CD45 APC-Cy7, and the second gate was based on CD4+CD3+ cells. The cells with the phenotype
CD45+CD3+CD4+CD127-FOXP3+ were considered to be Treg lymphocytes. Quadrants or gates were established based on the isotype controls.
doi:10.1371/journal.pone.0037393.g002
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EDTA-treated whole blood was incubated for 15 minutes in the
dark at room temperature with 20 mL CD3-FITC/CD8-PE/
CD45-PerCP/CD4-allophycocyanin (APC, BD Biosciences).
Erythrocytes were lysed with 450 mL lysing solution (BD
Biosciences).
Absolute numbers of the T helper subsets (Th1, Th17 and Treg)
for each individual were calculated based on the percentages of
each subset measured by flow cytometry.
Flow Cytometry
PBMC samples were analyzed using a FACSCanto flow
cytometer (BD Biosciences) and FlowJo software (Tree Star,
Ashland, OR, USA). Whole blood samples for counting absolute
cell numbers were acquired and analyzed using MultiSet software
in a FACSCalibur flow cytometer (BD Biosciences).
Statistical Analysis
The results were analyzed using SPSS 13.0 (SPSS Inc. and
Predictive Analytics, Chicago, IL, USA). Comparisons between
healthy volunteers and patients were performed using the Mann-
Whitney test; comparisons between patients’ samples (D7 versus
D0) were performed using the Wilcoxon Signed-Rank test.
P#0.05 was considered statistically significant.
Results
Epidemiology of the Cohort Studied
At the time of admission, of the 67 patients enrolled in the
study, 3% had sepsis, 17.9% had severe sepsis, and 79.1% had
septic shock. The mean age was 63.1617.3 years, and 62.7%
were male. The primary sources of infection were the lung
(41.8%), abdomen (25.4%), urinary tract (13.4%), bloodstream
(6.0%), skin or soft tissue (4.5%), operative wound (3%),
endocarditis (3%) and others (1.5%). The mean Acute Physiology
Figure 3. Strategy for the analysis of alternatively activated monocytes. Dot plots shown are representative of one healthy volunteer and
one septic patient. Twenty thousand events were acquired based on forward scatter versus side scatter parameters and CD14-positive stained cells.
The percentages of cells expressing CD163 or CD206 were determined with quadrants based on the isotype controls.
doi:10.1371/journal.pone.0037393.g003
T  Helper Lymphocyte Subsets and AAM in Sepsis
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37393and Chronic Health Evaluation II (APACHE II) score at
enrollment was 18.6, ranging from 6 to 35, and the mean
Sequential Organ Failure Assessment (SOFA) score was 7.6,
ranging from 0 to 14. The in-hospital mortality was 38.8%. The
mean age of healthy volunteers was 59.6616.4 years, and 62.5%
were male.
Th1, Th17 and Treg Subsets in Septic Patients
The percentages of T helper (CD3+CD82) lymphocytes
spontaneously producing IFN-c and IL-17 were higher in septic
patients at enrollment (D0) than in healthy volunteers (Table 1).
After PMA/Io stimulation, the percentage of T helper
(CD3+CD82) lymphocytes producing IFN-c was lower, and
the percentage producing IL-17 was higher in septic patients
than in healthy volunteers (Table 1). No differences in the
percentages of Treg cells were found between the two groups
(Table 1).
The absolute counts of CD4+ T lymphocytes in whole blood
dramatically decreased in D0 samples from septic patients
compared with healthy volunteers. Thus, the absolute numbers
of T helper (CD3+CD82) lymphocytes producing PMA/Io-
induced IFN-c and IL-17 and expressing Foxp3 (Treg) were lower
in septic patients than in the controls (Table 2).
T helper Subsets in Patients’ follow Up Samples
A spontaneous increased percentage of T helper (CD3+CD82)
lymphocytes producing IFN-c and IL-17 was observed in patients’
D0 and D7 samples compared with healthy individuals (Figures 4A
and B). Septic patients showed a dichotomous response after
stimulation with PMA/Io; they presented a lower percentage of
IFN-c-producing cells (Figure 4D) and an increased percentage of
IL-17-producing cells (Figure 4E) in admission samples (D0)
compared with healthy individuals. Thus, admission samples in
the group of septic patients with paired D0 and D7 samples
presented results similar to the whole cohort of patients. In follow-
up samples, a higher percentage of IFN-c and a lower percentage
of IL-17-producing cells were observed in D7 samples compared
with D0 samples. No differences were observed between the
samples from healthy volunteers and D7 samples for either
cytokine analyzed (Figures 4D and E). Additionally, no difference
was found in the percentage of regulatory T lymphocytes among
the different groups (Figure 4C).
Table 1. Percentages of T helper (CD3+CD82) lymphocytes producing IFN-c and IL-17, T helper (CD3+CD4+) expressing CD127-
Foxp3+ and monocytes (CD14 positive) expressing CD163 or CD206 in healthy volunteers and septic patients (D0 samples).
Healthy volunteers Septic patients
%n %n P values
T helper lymphocytes
IFN-c Control 0.07 30 0.12 59 0.020
(0.05–0.09) (0.05–0.21)
PMA/Io 21.40 30 10.40 59 0.001
(14.48–27.03) (7.15–20.20)
IL-17 Control 0.11 30 0.21 59 ,0.001
(0.07–0.15) (0.12–0.37)
PMA/Io 0.85 30 1.14 59 0.027
(0.65–1.31) (0.79–2.05)
Foxp3+CD1272 3.11 32 2.40 62 0.216
(1.99–5.40) (1.09–4.61)
Monocytes
CD163 0.00 32 23.73 62 ,0.001
(0.00–0.86) (3.85–39.46)
CD206 0.48 32 2.38 62 ,0.001
(0.00–1.00) (1.03–5.61)
Values represent the median and 25–75% quartile. n = number of individuals in each group. The Mann-Whitney test was applied.
doi:10.1371/journal.pone.0037393.t001
Table 2. Absolute counts of CD4+ T lymphocytes and
subpopulations (CD3+CD82) producing IFN-c and IL-17 after
PMA/Io stimulation, and T helper (CD3+CD4+) expressing
CD127-Foxp3+ in healthy volunteers (n=30) and septic
patients (D0 samples, n=46).
Healthy volunteers Septic patients
cell/m L cell/m L P values
Lymphocytes
CD4+ T 972.50 342.00 ,0.001
(781.00–1165.75) (159.50–577.50)
IFN-c 166.00 35.22 ,0.001
(124.89–283.58) (14.79–98.86)
IL-17 7.93 3.35 ,0.001
(5.93–12.63) (1.80–6.47)
Foxp3+CD1272 28.19 7.47 ,0.001
(16.20–49.11) (3.29–13.50)
Values represent the median and 25–75% quartile. The Mann-Whitney test was
applied.
doi:10.1371/journal.pone.0037393.t002
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The percentages of Th1, Th17 and Treg cells were analyzed in
relation to the patients’ in-hospital mortality. No differences were
observed between the percentages of the T helper (CD3+CD8+)
lymphocyte subsets at D0 between the survivors and the non-
survivors (Table 3). In follow-up samples, a higher percentage of
cells spontaneously producing IFN-c was found in D7 samples
compared with D0 samples from patients who had died
(Figure 5A). A decreased percentage of PMA/Io-induced IL-17-
producing cells was found in the survivors’ follow-up samples (D7)
compared with the admission samples, while the percentage
remained similar in non-survivors (Figure 5B). No changes in the
levels of Tregs were found between D7 and D0 samples that
correlated with clinical outcomes (Figure 5C).
Septic Patients showed Increased Expression of CD163
and CD206 on Monocytes
A striking difference in the percentage of monocytes expressing
CD163 or CD206 was found between healthy volunteers and
septic patients, with the highest values observed in septic patients
(Table 1).
In patients with sepsis, the percentages of cells expressing
CD163 was higher in CD14++CD162 (median: 29.6%) and
CD14++CD16+ (median: 27.00%) subsets than in the
CD14+CD16+ subset (median: 0.00%). Similarly, the expression
of CD206 was higher in CD14++CD162 (median: 2.83%) and
CD14++CD16+ (median: 5.25%) than in the CD14+CD16+
subset (median: 0.00%). The expression of CD163 was higher in
septic patients than in healthy volunteers in CD14++CD162
(29.18%, 25–75% quartile: 7.47–45.75% versus 0.00%, 25–75%
quartile: 0.00–2.21, respectively; P,0.001), CD14++CD16+
(26.98%, 25–75% quartile: 3.82–40.92% versus 0.00%, 25–75%
quartile: 0.00–0.00%, respectively; P,0.001) and CD14+CD16+
(0.00%, 25–75% quartile: 0.00–7.14% versus 0.00%, 25–75%
Figure 4. Percentages of T helper (CD3+CD82) producing IFN-c (Th1 - A/D) and IL-17 (Th17 - B/E), and percentages of Treg
(CD3+CD4+CD127-Foxp3+ - C) lymphocytes in healthy volunteers and septic patients with paired samples (D0 and D7).
n = number of individuals in each group. P values are shown. The Mann-Whitney test was used to compare healthy volunteer and patient
samples (D0 and D7), and the Wilcoxon Signed-Rank Test was used to compare D0- and D7-related samples.
doi:10.1371/journal.pone.0037393.g004
Table 3. Percentages of T helper lymphocytes producing IFN-
c, IL-17 (CD3+CD82), T helper (CD3+CD4+) expressing
CD1272Foxp3+ and monocytes (CD14 positive) expressing
CD163 or CD206 in septic patients at admission (D0), divided
into non-survivors (n=24) and survivors (n=35). Values
represent the median and 25–75% quartile.
Non-survivors Survivors
%% P values
T helper lymphocytes
IFN-c Control 0.16 0.12 0.588
(0.05–0.26) (0.06–0.20)
PMA/Io 10.03 12.8 0.294
(4.56–21.30) (8.04–18.60)
IL-17 Control 0.29 0.19 0.081
(0.16–0.42) (0.12–0.34)
PMA/Io 1.10 1.14 0.871
(0.81–1.94) (0.80–2.19)
Foxp3+CD1272 2.49 2.40 0.251
(1.51–5.94) (0.90–4.29)
Monocytes
CD163 26.63 23.51 0.378
(6.29–44.32) (3.77–39.22)
CD206 4.33 2.02 0.054
(1.56–6.99) (1.06–3.71)
The Mann-Whitney test was applied.
doi:10.1371/journal.pone.0037393.t003
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expression of CD206 was higher in septic patients than in the
controls in CD14++CD162 (2.83%, 25–75% quartile: 1.05–
6.31% versus 0.83%, 25–75% quartile: 0.35–1.70%, respectively;
P,0.001) and CD14++CD16+ (5.25%, 25–75% quartile: 0.81–
1.19% versus 0.08%, 25–75% quartile: 0.00–4.19, respectively;
P,0.001), and it was similar in CD14+CD16+ (0.00%, 25–75%
quartile: 0.00–2.30% versus 0.00%, 25–75% quartile: 0.00–
0.93%, respectively; P=0.069) monocytes.
The percentage of monocytes expressing CD163 or CD206
remained high in patients’ follow-up samples, with similar results
obtained in D7 samples compared with D0 samples; the
percentages at both time points (D0 and D7) were higher than
in healthy volunteers (Figures 6A and 6B).
Expression of CD163 and CD206 on Monocytes and
Patients’ Outcomes
Similar percentages of CD163-expressing monocytes were
found in the survivors and non-survivors. Additionally, there were
no significant differences in the percentages of CD206-positive
monocytes between the survivors and non-survivors (Table 3). No
differences were found between the D0 and D7 samples in
surviving and non-surviving patients for either of the receptors
analyzed (data not shown).
Discussion
Our results show profound lymphopenia and decreased CD4+T
cell counts in septic patients, as previously described [23,33]. This
low CD4+T cell number impacted all three of the subpopulations
we evaluated, Th1, Th17 and Treg, which presented reduced
absolute numbers. However, there was a diverse impact on the
different subsets of these cells, as evidenced by their differential
percentages in septic patients and healthy volunteers.
We found increased percentages of cells spontaneously produc-
ing IFN-c or IL-17, which is consistent with the ongoing
inflammatory process in septic patients. However, upon stimula-
tion with PMA/Io, a decreased percentage of cells producing IFN-
c and an increased percentage of cells producing IL-17 were
observed in admission samples from septic patients compared with
healthy volunteers. The observation of a lower percentage of T
helper lymphocytes producing IFN-c is consistent with previous
work showing a shift from Th1 to Th2 cytokine profiles following
trauma, burns and infection. In agreement with this, O’Sullivan et
al. [34] observed decreased production of IFN-c and increased
production of IL-4 in patients with burns and trauma, while
Heidecke et al. [35] found decreased T lymphocyte production of
IL-2, TNF-a and IFN-c, the latter in early lethal sepsis, and
unaffected production of IL-4 and IL-10 in patients with
peritonitis. The increased percentage of IL-17-producing T helper
lymphocytes in the peripheral blood of septic patients is consistent
with the increased percentage of monocytes expressing CD206,
which has been shown to be involved in triggering Th17 in
response to Candida albicans [36], and with the unchanged
percentage of Treg, which would have an inhibitory effect on
Th17 differentiation.
Most of the literature regarding the role of Th17 in disease
comes from studies using autoimmune models [6], yet there is
increasing evidence for a central role of Th17 in infections. The
IL-17 receptor (IL-17R) has a protective role in a model of
Klebsiella pneumoniae lung infection in mice [37]. Impaired
neutrophil mobilization and influx into infected organs were also
found in IL-17R(2/2) mice infected with Candida albicans,
whereas the expression of IL-17A protected wild-type mice from
a lethal challenge [38]. In contrast, Flierl et al. showed that the
intravenous injection of anti-IL-17 improved survival in mice
subjected to cecal ligation and puncture (CLP)-induced sepsis and
decreased the serum levels of IL-6 and TNF-a [39]. Th17 cells are
a source of IL-21 and IL-22, in addition to IL-17A and IL-17F. In
a recent report, increased IL-22 plasma levels were found in
patients with abdominal sepsis [40]. Our finding of an increased
proportion of IL-17-producing T helper lymphocytes in septic
Figure 5. Percentages of T helper (CD3+CD82) producing IFN-c (Th1 - A/D) and IL-17 (Th17 - B/E), and percentages of Treg
(CD3+CD4+CD127Foxp3+ - C) lymphocytes in non-survivors (n=14) and survivors (n=17) at admission (D0) and after 7 days (D7) in
patients with follow-up samples. *P,0.05 (Wilcoxon Signed-Rank Test).
doi:10.1371/journal.pone.0037393.g005
T  Helper Lymphocyte Subsets and AAM in Sepsis
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37393patients (D0) suggests a shift in the differentiation of T helper
lymphocytes toward an inflammatory pattern that will, in turn,
drive innate immune cells toward activation. Previous work from
our group and from others support the notion that there is a state
of neutrophil activation in septic patients, at least with respect to
phagocytosis, generation of reactive oxygen species [27,41] and
TLR pathway gene expression [42].
We found reduced Treg cell absolute numbers in septic patients
at the time of admission, reflecting the decreased numbers of
CD4+T cells, but the percentage of Tregs remained unchanged
between patients and healthy volunteers. In a pioneering report,
Monneret et al. found an increased percentage of TCD4+CD25+
cells in septic patients [8], due to a decreased proportion of
TCD4+CD252 cells [9]. On the other hand, Hein et al. found
similar proportion of Tregs in admission samples from septic
patients compared with healthy volunteers [13]. Our results
further support that the reported increase in the percentages of
Tregs among T helper cells in septic patients is inconsistent across
all septic patient populations.
In contrast to our results and previous ones showing modulation
of Th cell sub-populations in septic patients, Venet and coworkers
[43] recently showed that all CD4+T lymphocyte subsets were
equally diminished in septic shock patients. They evaluated CD4+
T cell-specific transcription factors for Th1 (T-bet), Th2 (GATA-
3), Treg (Foxp3) and Th17 (RORcT) in septic patients during the
first 48 h of shock. Possible explanations for the discrepancy
among the studies may be the variations in the approaches used
for collecting the samples and for characterizing T helper sub-
populations.
In the follow-up samples the percentage of IFN-c-producing T
helper lymphocytes upon PMA/Io after 7 days of therapy was
higher than at admission, whereas the percentage of IL-17-
producing T helper lymphocytes was lower. Thus, the proportions
of both sub-populations after 7 days of therapy were similar to
those in healthy volunteers, reversing the Th1 down-regulation
and Th17 up-regulation observed at admission. This may indicate
an effort to restore homeostasis during therapy. Interestingly, while
the percentages of Th1 and Th17 at admission (D0) did not
correlate with in-hospital survival rates, the percentages of IFN-c-
spontaneously producing T helper cells were higher at day 7 than
at admission in the non-survivors, and the percentage of PMA/Io-
induced IL-17 cells was lower at day 7 than at admission in the
survivors. These results suggest that the sustained state of Th1 and
Th17 activation may be deleterious in septic patients. Again, no
difference in the percentage of Tregs was found during patient
follow-up when compared with D0.
To further evaluate the mononuclear cell subpopulations in
septic patients, we measured the expression of markers for
alternatively activated monocytes. We found a dramatic increase
in the percentage of monocytes expressing CD163 and CD206 in
septic patients. CD163 expression on neutrophils and monocytes
has been previously evaluated in critically ill neonates and
children. It was shown that the CD163 mean fluorescence
intensity for neutrophils and monocytes and the CD163 index
for neutrophils could be used to discriminate between SIRS and
sepsis in this population [44]. sCD163, the soluble form of CD163,
has been evaluated as a serum marker for bacteremia, and its
levels have been shown to be correlated with clinical outcomes
[45,46]. In our study, there was no association between the cell
surface expression of CD163 and clinical outcomes, but the
striking up-regulation of CD163 suggests it may be a good
diagnostic marker. Future studies with critically ill non-septic
patients are needed to address this issue. In contrast, there was a
trend toward higher percentages of monocytes expressing CD206
in the non-surviving patients. However, the small number of
patients in the survival and non-survival groups necessitates
further studies for the evaluation of its prognostic value.
Human and mice monocytes have also been characterized as
classical and non-classical or inflammatory and resident mono-
cytes based on CD14/CD16 (for humans) and Ly6C/CX3CR1/
CCR2 (for mice) expression [47–49]. The expression of CD16 is
increased in M1 monocytes and the expression of CD14, CD206
and CD163 is increased in M2 monocytes [50]. In a study
evaluating HIV-infected individuals and healthy volunteers,
Tippett et al. reported that the expression of CD163 was highest
in CD14++CD162, intermediate in CD14++CD16+ and lowest
in CD14+CD16++ monocyte subsets. CD163 expression was
higher in HIV-infected individuals than in controls only in the
Figure 6. Percentages of AAM expressing CD163 (A) and CD206 (B) in healthy volunteers and septic patients with paired samples
(D0 and D7). n= number of individuals in each group. P values are shown. The Mann-Whitney test was used to compare healthy volunteer and
patient samples (D0 and D7), and the Wilcoxon Signed-Rank Test was applied to patients’ related samples.
doi:10.1371/journal.pone.0037393.g006
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monocyte subsets CD14++CD162, CD14++CD16+ and
CD14+CD16+, we found higher expression of CD163 and
CD206 in septic patients in the CD14++CD162 and
CD14++CD16+ subsets than in the CD14+CD16+ subset.
Additionally, the expression levels of CD163 and CD206 were
higher in septic patients than in controls in all monocyte subsets,
except for CD206 in CD14+CD16+.
The increased proportion of monocytes expressing markers for
alternatively activated monocytes/macrophages found in our
study may result from a lower proportion of IFN-c-producing T
helper cells, which induce the classically activated macrophages, or
from the previously described increased Th2 profile found in septic
patients. CD4+CD25+Foxp3+ regulatory T cells also induce
alternatively activated monocytes, with up-regulation of both
receptors on monocytes [22], yet we found similar percentages of
Tregs in patients and healthy volunteers. IL-21, a cytokine linked
to the Th17 profile, induces Th2 effector functions and alternative
macrophage activation [21], and conversely, the mannose receptor
has been shown to be crucial for the induction of IL-17 by Candida
albicans [36]. Thus, the increased expression of CD206 may be
related to the increased Th17 we found in septic patients.
However, despite the clear interplay between monocytes and T
helper lymphocytes in the differentiation of subpopulations, we did
not find a correlation between T helper lymphocyte subpopula-
tions and expression of markers for alternatively activated
monocytes (data not shown). We are currently evaluating the
levels of circulating cytokines related to Th1, Th2, Treg and Th17
profiles in septic patients to help understand the modulation of
mononuclear subsets in septic patients.
It has been well documented that monocytes from septic
patients fail to produce TNF-a and IL-6 [3,4], while the
production of IL-10 seems to be less affected [4,24]. Previous
studies by our group also showed that monocytes from patients
with severe sepsis and septic shock produce low amounts of
inflammatory cytokines while preserving the ability to generate
reactive oxygen species (ROS) [24,27]. Supporting these results,
monocytes that were tolerant to LPS in vitro produced low amounts
of IL-6, showed preserved phagocytosis and increased levels of
ROS [52]. Altogether, the above results clearly indicate a
reprogramming of monocyte/macrophage function during sepsis
and LPS-induced tolerance [28,53]. This phenotype may corre-
spond, at least in part, to alternative monocyte activation. The
increased expression of CD206 and CD163 on circulating
monocytes in our study supports the conclusion that alternative
activation of monocytes occurs during sepsis. Future studies
combining cell surface expression and functional evaluation of
circulating monocytes may provide relevant information about the
different phenotypes of monocytes during sepsis, which would
account for a broad spectrum of monocyte differentiation or
activation.
There are some limitations to this study. Because no specific
marker was used to exclude NKT cells from the CD3+CD82
gated cells, we should consider that these cells may also contribute
to the IFN-c and IL-17-producing cells. Without evaluating the
Th2 subpopulation, our analysis of mechanisms inducing mono-
cyte differentiation toward an M2 profile is incomplete. Addition-
ally, while the use of flow cytometry for the detection of
intracellular cytokines allows for the functional characterization
of T lymphocyte subtypes at the cellular level, in vitro stimulation
may lead to cell division or death that may differ between healthy
volunteers and septic patients. To address this in the future, a
viability marker could be used to exclude dead or early stage
apoptosis cells in the flow cytometry analysis. As with other studies,
the evaluation of peripheral blood cell function in septic patients
may not correspond to the processes in other organs and tissues.
We did not perform functional studies of monocytes, which would
add relevant information. Nevertheless, the expression of CD206
and CD163 on monocytes of septic patients clearly indicates a
pattern of cell differentiation.
In conclusion, patients with sepsis presented an increased
percentage of Th17 and a decreased percentage of Th1 cells upon
treatment with PMA/Io, and these changes were reversed after
7 days of therapy, while no changes were found in percentages of
the Treg subset. We found a dramatic increase in the percentage
of monocytes expressing CD206 and CD163, indicating the
alternative activation of monocytes, which supports previous
studies showing a reprogramming of monocyte function during
sepsis.
Acknowledgments
We are grateful to Maria Aparecida Dalboni from the Division of
Nephrology for providing access to the FACSCanto cytometer.
Author Contributions
Conceived and designed the experiments: MKB MCS OR FRM ES RS.
Performed the experiments: MKB MCS. Analyzed the data: MKB MCS
RS. Wrote the paper: MKB MCS OR FRM ES RS.
References
1. Salomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, et al.
(2008) TLR signaling pathway in patients with sepsis. Shock 30: 73–77.
2. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis.
N Engl J Med 348: 138–150.
3. Munoz C, Carlet J, Fitting C, Misset B, Ble ´riot JP, et al. (1991) Dysregulation of
in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:
1747–1754.
4. Rigato O, Salomao R (2003) Impaired production of interferon-gamma and
tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients
with sepsis. Shock 19: 113–116.
5. Salomao R, Brunialti MK, Kalla ´s EG, Martins PS, Rigato O, et al. (2002)
Lipopolysaccharide-cell interaction and induced cellular activation in whole
blood of septic patients. J Endotoxin Res 8: 371–379.
6. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector
functions of T(H)17 cells. Nature 453: 1051–1057.
7. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and
immune tolerance. Cell 133: 775–787.
8. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, et al. (2003) A Marked
elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced
immunoparalysis. Crit Care Med 31: 2068–2071.
9. Venet F, Pachot A, Debard AL, Bohe ´ J, Bienvenu J, et al. (2004) Increased
percentage of CD4+CD25+ regulatory T cells during septic shock is due to the
decrease of CD4+CD252 lymphocytes. Crit Care Med 32: 2329–2331.
10. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, et al. (2009) Increased
circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to
lymphocyte anergy in septic shock patients. Intensive Care Med 35: 678–686.
11. Scumpia PO, Delano MJ, Kelly KM, O’Malley KA, Efron PA, et al. (2006)
Increased natural CD4+CD25+ regulatory T cells and their suppressor activity
do not contribute to mortality in murine polymicrobial sepsis. J Immunol 177:
7943–7949.
12. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, et al. (2005) Adoptive transfer
of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial
clearance and improves survival in polymicrobial sepsis. J Immunol 174:
7141–7146.
13. Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, et al. (2010) The
relationship between CD4+CD25+CD1272 regulatory T cells and inflamma-
tory response and outcome during shock states. Crit Care 14: R19.
14. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005)
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct
from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123–1132.
T  Helper Lymphocyte Subsets and AAM in Sepsis
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e3739315. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal
developmental pathways for the generation of pathogenic effector Th17 and
regulatory T cells. Nature 441: 235–238.
16. Stockinger B, Veldhoen M, Martin B (2007) Th17 T cells linking innate and
adaptive immunity. Semin Immunol 19: 353–361.
17. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:
23–35.
18. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage
activation. Nat Rev Immunol 8: 958–969.
19. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances
murine macrophage mannose receptor activity: a marker of alternative
immunologic macrophage activation. J Exp Med 176: 287–292.
20. Van Gorp H, Delputte PL, Nauwynck HJ (2010) Scavenger receptor CD163, a
Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol
47: 1650–1660.
21. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr., et al.
(2006) The IL-21 receptor augments Th2 effector function and alternative
macrophage activation. J Clin Invest 116: 2044–55.
22. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, et al. (2007)
CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human
monocytes/macrophages. Proc Natl Acad Sci USA 104: 19446–19451.
23. Lin RY, Astiz ME, Saxon JC, Rackow EC (1993) Altered leukocyte
immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and
IL-2R expression. Chest 104: 847–853.
24. Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM,
et al. (2006) TLR2, TLR4, CD14, CD11B, and CD11C expressions on
monocytes surface and cytokine production in patients with sepsis, severe sepsis,
and septic shock. Shock 25: 351–357.
25. Monneret G, Lepape A, Voirin N, Bohe ´ J, Venet F, et al. (2006) Persisting low
monocyte human leukocyte antigen-DR expression predicts mortality in septic
shock. Intensive Care Med 32: 1175–1183.
26. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, et al. (1995)
Downregulation of proinflammatory cytokine release in whole blood from septic
patients. Blood 85: 1341–1347.
27. Martins PS, Brunialti MK, Martos LS, Machado FR, Assunc ¸ao MS, et al. (2008)
Expression of cell surface receptors and oxidative metabolism modulation in the
clinical continuum of sepsis. Crit Care 12: R25.
28. Cavaillon JM, Adib-Conquy M (2006) Bench-to-bedside review: endotoxin
tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 10: 233.
29. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions
for sepsis and organ failure and guidelines for the use of innovative therapies in
sepsis. The ACCP/SCCM Consensus Conference Committee. American
College of Chest Physicians/Society of Critical Care Medicine. Chest 101:
1644–1655.
30. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, et al. (1995) Direct
demonstration of cytokine synthesis heterogeneity among human memory/
effector T cells by flow cytometry. Blood 86: 1408–1419.
31. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127
expression inversely correlates with FoxP3 and suppressive function of human
CD4+ T reg cells. J Exp Med 203: 1701–1711.
32. Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, et al. (2011)
Comparative approach to define increased regulatory T cells in different cancer
subtypes by combined assessment of CD127 and FOXP3. Clin Dev Immunol
2011: 734036. 734036 p.
33. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr., Hui JJ, et al. (2001)
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+
T lymphocytes in humans. J Immunol 166: 6952–696.
34. O’Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, et al. (1995)
Major injury leads to predominance of the T helper-2 lymphocyte phenotype
and diminished interleukin-12 production associated with decreased resistance
to infection. Ann Surg 222: 482–492.
35. Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, et al. (1999)
Selective defects of T lymphocyte function in patients with lethal intraabdominal
infection. Am J Surg 178: 288–292.
36. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, et al.
(2009) The macrophage mannose receptor induces IL-17 in response to Candida
albicans. Cell Host Microbe 5: 329–340.
37. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, et al. (2001)
Requirement of interleukin 17 receptor signaling for lung CXC chemokine
and granulocyte colony-stimulating factor expression, neutrophil recruitment,
and host defense. J Exp Med 194: 519–527.
38. Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of
interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect
Dis 190: 624–631.
39. Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, et al. (2008) Adverse
functions of IL-17A in experimental sepsis. FASEB J 22: 2198–2205.
40. Bingold TM, Ziesche ´ E, Scheller B, Sadik CD, Franck K, et al. (2010)
Interleukin-22 detected in patients with abdominal sepsis. Shock 34: 337–340.
41. Martins PS, Kallas EG, Neto MC, Dalboni MA, Blecher S, et al. (2003)
Upregulation of reactive oxygen species generation and phagocytosis, and
increased apoptosis in human neutrophils during severe sepsis and septic shock.
Shock 20: 208–212.
42. Salomao R, Brunialti MK, Gomes NE, Mendes ME, Diaz RS, et al. (2009) Toll-
like receptor pathway signaling is differently regulated in neutrophils and
peripheral mononuclear cells of patients with sepsis, severe sepsis, and septic
shock. Crit Care Med 37: 132–139.
43. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, et al. (2010) Early
assessment of leukocyte alterations at diagnosis of septic shock. Shock 34:
358–363.
44. Groselj-Grenc M, Ihan A, Derganc M (2008) Neutrophil and monocyte CD64
and CD163 expression in critically ill neonates and children with sepsis:
comparison of fluorescence intensities and calculated indexes. Mediators
Inflamm 2008: 202646. 202646 p.
45. Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, et al. (2006)
Macrophage serum markers in pneumococcal bacteremia: Prediction of survival
by soluble CD163. Crit Care Med 34: 2561–2566.
46. Gaı ¨ni S, Pedersen SS, Koldkaer OG, Pedersen C, Moestrup SK, et al. (2008)
New immunological serum markers in bacteraemia: anti-inflammatory soluble
CD163, but not proinflammatory high mobility group-box 1 protein, is related
to prognosis. Clin Exp Immunol 151: 423–431.
47. Passlick B, Flieger D, Ziegler-Heitbrock HW (1989) Identification and
characterization of a novel monocyte subpopulation in human peripheral
blood. Blood 74: 2527–2534.
48. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev
Immunol 5: 953–964.
49. Serbina NV, Jia T, Hohl TM, Pamer EG (2008) Monocyte-mediated defense
against microbial pathogens. Annu Rev Immunol 26: 421–452.
50. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The
chemokine system in diverse forms of macrophage activation and polarization.
Trends Immunol 25: 677–686.
51. Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, et al. (2011)
Differential expression of CD163 on monocyte subsets in healthy and HIV-1
infected individuals. PLoS One 6: e19968.
52. Fernandes ML, Mendes ME, Brunialti MK, Salomao R (2010) Human
monocytes tolerant to LPS retain the ability to phagocytose bacteria and
generate reactive oxygen species. Braz J Med Biol Res 43: 860–868.
53. Mendes ME, Baggio-Zappia GL, Brunialti MK, Fernandes MD, Rapozo MM,
et al. (2011) Differential expression of toll-like receptor signaling cascades in
LPS-tolerant human peripheral blood mononuclear cells. Immunobiology 216:
285–295.
T Helper Lymphocyte Subsets and AAM in Sepsis
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37393
 